Get the app
US › Healthcare

CAMP4 THERAPEUTICS CORPORATION (CAMP)

US · Healthcare · Biotechnology

$3.17-8.12%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$1.8M
Revenue YoY
+18.8%
Net profit
$-33.5M
EPS
$-0.22
EPS estimate
$-0.24
Net margin
-1,884.8%

EPS came in at -0.22 against a street estimate of -0.24 — a beat of 8.3%.

Key statistics

Market cap
$236.6M
Forward P/E
0.0
P/B
9.11
Book value
$-0.01
EPS (TTM)
$-2.32
52-week high
$7.75
52-week low
$2.86
50-day MA
$4.18
200-day MA
$4.41

Analyst view

Analysts rate CAMP4 THERAPEUTICS CORPORATION a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $10.57.

Shareholding

Insiders
9.65%
Institutions
79.74%

Largest institutional holders

FundStake
HHG PLC10.05%
Jupiter Topco LLC10.05%
5AM Venture Management, LLC9.35%
FMR Inc7.82%
Vivo Capital, LLC6.77%
Balyasny Asset Management LLC4.10%
Adage Capital Partners Gp LLC3.12%
Trails Edge Capital Partners, LP3.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CAMP4 THERAPEUTICS CORPORATION — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.